Last updated on November 2019

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC


Brief description of study

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Detailed Study Description

Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the starting dose of talazoparib in combination with enzalutamide through assessment of target safety events and PK at select sites. Part 2 is a randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus enzalutamide in patients with mCRPC.

Clinical Study Identifier: NCT03395197

Find a site near you

Start Over

South Jordan Health Center -University of Utah

South Jordan, UT United States
9.82miles
  Connect »

University of Utah, Huntsman Cancer Hospital

Salt Lake City, UT United States
9.86miles
  Connect »

University of Utah, Huntsman Cancer Institute

Salt Lake City, UT United States
9.86miles
  Connect »

Huntsman Cancer Hospital

Salt Lake City, UT United States
9.86miles
  Connect »